Skip to main content
. 2012 Oct 29;121(1):197–206. doi: 10.1182/blood-2012-03-417667

Figure 3.

Figure 3

Toxicities. (A) Highest toxicity level of key symptoms (fever in the absence of signs of infection, fatigue, skin rash, local reactions, nausea, vomiting, anorexia, insomnia, dizziness, and syncope) experienced by BM and PBSC donors at baseline, during pericollection period, and after donation. (Day 2 is the second day of filgrastim; day 5 is the first day of apheresis.) (B) Toxicities among BM and PBSC donors on the day noted to have the highest level of toxicity (1-2 days post-BM collection and day + 5 from start of G-CSF for PBSC). (C) Common toxicities among BM and PBSC donors on the day noted to have the highest level of toxicity (1-2 days post-BM collection and day + 5 from start of G-CSF for PBSC), and at selected time points after donation.